{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:13:08Z","timestamp":1789146788987,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109594","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:49Z","timestamp":1787755969000},"page":"109594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"220","author":[{"given":"Damien","family":"Humbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurine","family":"Basset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Toffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Odier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Hominal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Herreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mc Leer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Swalduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109594_b0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109594_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","article-title":"Lung cancer in patients who have never smoked \u2014 an emerging disease","volume":"21","author":"LoPiccolo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK -positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109594_b0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109594_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.05.692","article-title":"Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study","author":"Shaw","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0030","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0035","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-3260","article-title":"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants","volume":"18","author":"Heuckmann","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109594_b0040","article-title":"Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 fusion and resistance mutations in patients with non\u2013small-cell lung cancer","volume":"4","author":"Mezquita","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0045","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","article-title":"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer","volume":"68","author":"Young","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109594_b0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12967-021-02982-4","article-title":"Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers","volume":"19","author":"Xia","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2026.109594_b0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jtho.2021.09.016","article-title":"Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged NSCLC","volume":"17","author":"Song","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41588-020-0669-3","article-title":"Guidelines for human gene nomenclature","volume":"52","author":"Bruford","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2026.109594_b0065","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0070","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109594_b0080","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cllc.2015.09.002","article-title":"Anaplastic lymphoma kinase variants and the percentage of ALK-positive tumor cells and the efficacy of crizotinib in advanced NSCLC","volume":"17","author":"Lei","year":"2016","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109594_b0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12967-016-1061-z","article-title":"Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants","volume":"14","author":"Cha","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2026.109594_b0095","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109594_b0105","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027038","article-title":"The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: a meta-analysis","volume":"100","author":"Lan","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.lungcan.2026.109594_b0110","first-page":"84","article-title":"PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors","author":"Lasvergnas","year":"2023","journal-title":"Respir. Med. Res."},{"key":"10.1016\/j.lungcan.2026.109594_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/biom13060991","article-title":"High PD-L1 expression correlates with an immunosuppressive tumour immune microenvironment and worse prognosis in ALK-rearranged non-small cell lung cancer","volume":"13","author":"Tian","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.lungcan.2026.109594_b0120","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT017","article-title":"Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed","volume":"84","author":"J\u00e4nne","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109594_b0125","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109594_b0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:53:00Z","timestamp":1789145580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0169500226006550"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109594","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109594"}}